DanCann Pharma A/S: Standardized medicinal cannabis products are essential for the medical profession – and ultimately for the patients
COPENHAGEN, Denmark, 19 August 2022 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) comment on the importance of standardization of medicinal cannabis productsThe Danish biopharmaceutical manufacturer DanCann Pharma has established the high-tech production facility, Biotech Pharm1 (“BP1"), in order to be able to produce standardized medicinal cannabis products. The facility is built based on best practice from the pharmaceutical industry in combination with advanced environmentally controlled agricultural technology and vertical agriculture. BP1 is designed to